Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The newly published results of two small clinical trials suggest that two novel antibiotics could provide safer alternatives ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Recent research introduces a soft, injectable material designed for use in the eye to help protect and support damaged ...

Discover new treatments like ART-123 advancing toward approval to prevent long-term nerve damage caused by ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

Numbness in your legs can be caused by many health conditions, including peripheral neuropathy, a herniated disc, or nerve damage from an injury. The correct diagnosis can help you get the right ...

We appreciate the responses to our Article,1 which suggest that the health cost of paying for new pharmaceuticals in the National Health Service (NHS), estimated at £1·25 million quality-adjusted life ...

Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis ...

New DNA test predicts chemotherapy resistance before treatment, potentially sparing patients from ineffective toxic drugs.

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...